Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12
Matthew C. Cheung, Annette E. Hay, Michael Crump, Kevin R. Imrie, Yuyao Song, Shazia Hassan, Nancy Risebrough, Jonathan Sussman, Stephen Couban, David Macdonald, Vishal Kukreti, C. Tom Kouroukis, Tara Baetz, David Szwajcer, Pierre Desjardins, Lois Shepherd, Ralph M. Meyer, Al Le, Bingshu E. Chen, Nicole Mittmann
Dive into the research topics of 'Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12'. Together they form a unique fingerprint.